title: Effective achievement of hemoglobin stability with once-monthly C.E.R.A. in peritoneal dialysis patients: a prospective study.
abstract: BACKGROUND
  Correction of low hemoglobin (Hb) levels is associated with improved survival and greater quality of life in dialysis patients, but frequent administration of erythropoiesis stimulating agent (ESA) therapy is unsatisfactory for peritoneal dialysis patients.
  
  
  OBJECTIVE
  The objective of this study was to assess Hb stability in an unselected population of maintenance peritoneal dialysis patients receiving once-monthly treatment with C.E.R.A., a continuous erythropoietin receptor activator.
  
  
  METHODS
  In a prospective, non-interventional, single-arm study at 33 Germany dialysis centers, peritoneal dialysis patients with or without ESA treatment prior to study entry received once-monthly treatment with C.E.R.A. Hb stability was assessed by the proportion of patients for whom all measured Hb values during months 6-8 (the evaluation phase) were within the range 11-12, 11-13, 10-12 or 11-12.5 g/dL.
  
  
  RESULTS
  220 patients received at least one dose of C.E.R.A. During the evaluation phase, 185 patients provided ≥1 Hb measurement (efficacy population) and 162 patients provided ≥2 Hb measurements (the modified efficacy population). The mean (SD) time between C.E.R.A. doses was 28.2 (7.2) days and mean (SD) C.E.R.A. dose was 109 (57) μg per application. Mean (SD) Hb level was 11.1 (1.4) g/dL at baseline and 11.5 (1.3) g/dL at the end of the study (modified efficacy population). The primary efficacy variable, all measured Hb values in the range 11-12 g/dL, was 18.4 % (34/185) and 14.8 % (24/162) in the efficacy and modified efficacy populations, respectively. The mean (SD) maximum intra-individual fluctuation in Hb level was 0.56 (0.50) g/dL in the efficacy population and 0.58 (0.49) g/dL in the modified efficacy population, with maximum intra-individual fluctuation ≤1 g/dL in 85.4 % (158/185) and 83.3 % (135/162) of patients, respectively. No adverse drug reactions were reported during the study.
  
  
  CONCLUSIONS
  In this large population of maintenance peritoneal dialysis patients, once-monthly administration of C.E.R.A. achieved a high degree of Hb stability and was well-tolerated.
authors: Nephrology Center, Gartenstrasse 8, 40822, Mettmann, Germany, koch@dialyse-mettmann.de.
authors: Michael
authors: M
authors: Koch
authors: Wolfgang
authors: W
authors: Treiber
authors: Danilo
authors: D
authors: Fliser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood; D005260:Female; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods* / Q000639:trends; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011446:Prospective Studies; D017467:Receptors, Erythropoietin / Q000097:blood*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006454:Hemoglobins; D017467:Receptors, Erythropoietin; C508420:continuous erythropoietin receptor activator; D004921:Erythropoietin; D011092:Polyethylene Glycols
references: Clin Chem. 2007 Apr;53(4):766-72
references: 17332152
references: Int J Artif Organs. 2009 Nov;32(11):787-93
references: 20020410
references: Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46
references: 17699476
references: Clin J Am Soc Nephrol. 2008 Jan;3(1):133-8
references: 18045862
references: BMC Nephrol. 2009 Oct 24;10:33
references: 19852833
references: Perit Dial Int. 2005 Nov-Dec;25(6):564-9
references: 16411523
references: J Nephrol. 2003 Sep-Oct;16(5):697-702
references: 14733416
references: Nephrol Dial Transplant. 2004 Jan;19(1):121-32
references: 14671047
references: Curr Med Res Opin. 2007 May;23(5):969-79
references: 17519064
references: Perit Dial Int. 2009 Feb;29 Suppl 2:S145-8
references: 19270204
references: Curr Med Res Opin. 2009 Dec;25(12):2971-6
references: 19842997
references: Clin Nephrol. 2011 Jul;76(1):9-15
references: 21722600
references: Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47
references: 15206425
references: Perit Dial Int. 2007 Jun;27 Suppl 2:S205-9
references: 17556305
references: Kidney Int. 2005 Sep;68(3):1337-43
references: 16105069
references: Nephrol Dial Transplant. 2000;15 Suppl 3:23-8
references: 11032354
references: Ther Apher Dial. 2008 Feb;12(1):19-27
references: 18257808
references: Int J Clin Pract. 2011 Jan;65(1):64-72
references: 21091595
references: Curr Med Res Opin. 2010 May;26(5):1083-9
references: 20225992
references: Hemodial Int. 2012 Jan;16(1):11-9
references: 22098689
references: Perit Dial Int. 2012 Mar-Apr;32(2):177-82
references: 22045101
references: Am J Kidney Dis. 2005 Oct;46(4):650-60
references: 16183420
references: Scand J Urol Nephrol. 1997 Apr;31(2):183-7
references: 9165584
references: Int Urol Nephrol. 2003;35(4):535-41
references: 15198163
references: Pediatr Nephrol. 1997 Oct;11(5):628-30
references: 9323294
references: Nephrol Dial Transplant. 2009 Feb;24(2):348-54
references: 19037082
references: Nephron Clin Pract. 2010;115 Suppl 1:c153-86
references: 20413947
references: Clin Pharmacol Ther. 1991 Dec;50(6):702-12
references: 1752115
references: Adv Perit Dial. 2011;27:60-4
references: 22073831
references: Curr Med Res Opin. 2004 Sep;20(9):1501-10
references: 15383200
references: Nephrol Dial Transplant. 2001 Oct;16(10):1971-4
references: 11572880
references: Clin J Am Soc Nephrol. 2006 Nov;1(6):1211-5
references: 17699350
references: Nephrol Dial Transplant. 2010 Dec;25(12):4009-17
references: 20522670
references: J Am Soc Nephrol. 2004 Jan;15(1):174-9
references: 14694170
references: Kidney Int. 2004 May;65(5):1864-9
references: 15086928
references: Nephrol Dial Transplant. 1998 Jul;13(7):1763-9
references: 9681725
references: J Am Soc Nephrol. 1999 Nov;10(11):2392-5
references: 10541299
references: Lancet. 2007 Oct 20;370(9596):1415-21
references: 17950856